Biomarker of Stent Restenosis Through Metabolomics
not been a widely recognized branch of omics, has drawn considerable attention of late. Metabolomic profiling is now possible owing to recent progress in mass spectrometry and analytical software. Metabolomics has some obvious benefits over genomic and proteomic approaches. The human metabolome is significantly smaller (3-4,000 metabolites), and therefore much simpler to analyze in comparison with the genome and proteome, which comprise approximately 25,000 genes and 1,000,000 proteins, respectively. 15-17 Furthermore, the metabolome represents an individual's clinical phenotype. Alterations in the genome and proteome do not always relate to the individual's clinical phenotype because of homeostatic mechanisms. The metabolome is a unique chemical fingerprint derived from specific protein enzymatic functions; therefore, changes in the metabolome reflect changes in the clinical phenotype.
The concept of metabolomics has recently been introduced into the field of medicine. Many hydrophilic metabolites (ie, organic acids and amino acids) are closely related to the primary core metabolic functions, such as energy production and amino acid synthesis and conversion. Based on this, we believe that hydrophilic metabolomics can be used to identify fingerprints and disease biomarkers of specific biological activities. Gas chromatography/mass spectrometry (GC/MS) is one of the commonly used techniques in hydrophilic metabolomics because of its many technical advantages, including separation capability, larger spectrum libraries, robustness, and sensitivity. 18 Therefore, we aimed to apply GC/MS-based metabolomics to clinical cardiovascular medicine in this study. We investigated the hydrophilic metabolome in CAD patients with well-controlled disease according to the guidelines of the Japanese Circulation Society, and determined specific metabolomic alterations related to stent restenosis.
Methods

Patient Characteristics
The study group comprised 86 male patients admitted to Kobe University Hospital between July 2008 and December 2009 for follow-up coronary angiography, which was 6 months after stent implantation (Figure 1) . Exclusion criteria were as follows: active inflammation (C-reactive protein [CRP] >1.0 mg/dl), renal disease (serum creatinine >3.0 mg/dl or ongoing hemodialysis), and onset of cancer in the previous 5 years. Twenty-three patients had major restenotic lesions (≥75% stenosis) and were required to undergo target lesion revascularization. Of the remaining, 16 patients presented with de novo atherosclerotic lesions and 47 with minor restenotic lesions (≤50% stenosis). These patients with minor restenotic lesions were used as the age-and gender-matched control group. Patient characteristics of each group are shown in Table 1 . After an overnight fast, blood samples were collected from each patient on the morning of the coronary angiography procedure. Blood samples were immediately centrifuged at 900 g for 10 min at 4°C, and the serum was transferred to a clean tube and stored at −80°C until further use.
All patients provided written informed consent, and this study was approved by the Institutional Review Board of the Kobe University School of Medicine.
Sample Collection and Sample Preparation
Serum hydrophilic metabolomics were performed according to the methods used in our previous report. 19 Low-molecularweight metabolites were extracted as follows: 50 μl of serum was mixed with 250 μl of methanol-water-chloroform solvent mixture (2.5:1:1, v/v/v) containing 10 μl of an aqueous solution of 2-isopropylmalic acid (1.0 mg/ml in distilled water; Sigma-Aldrich, Tokyo, Japan) as an internal standard. The solution was shaken at 1,200 rpm for 30 min at 37°C, followed by centrifugation at 22,000 g for 3 min at 4°C. Next, 225 μl of the supernatant was transferred to a clean tube, to which 200 μl of distilled water was added. The resulting solution was centrifuged at 22,000 g for 3 min at 4°C, and 250 μl of supernatant was transferred to a clean tube and lyophilized using a freeze dryer. For oximation, 40 μl of methoxyamine hydrochloride (20 mg/ml in pyridine; Sigma-Aldrich) was mixed with a lyophilized sample and shaken at 1,200 rpm for 90 min at 30°C. Subsequently, 20 μl of N-methyl-N-trimethylsilyl-trifluoroacetamide (GL Science, Tokyo, Japan) was added for derivatization and the mixture was incubated at 1,200 rpm for 30 min at 37°C, following which it was centrifuged at 22,000 g for 5 min at 4°C. This supernatant was used for GC/MS analysis. 
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GC/MS Analysis
GC/MS analysis was performed in the Integrated Center for Mass Spectrometry, Kobe University Graduate School of Medicine, using a GCMS-QP2010 Ultra (Shimadzu Co, Kyoto, Japan) with a fused silica capillary column (CP-SIL 8 CB low bleed/MS; 30 m×0.25 mm inner diameter, 0.25 μm film thickness; Agilent Co, Palo Alto, CA, USA). The front inlet temperature was 230°C and the helium gas flow rate through the column was 39.0 cm/s. The column was maintained at 80°C for 2 min isothermally, following which the temperature was increased to 330°C at the rate of 15°C/min and maintained for 6 min isothermally. The transfer line and ion-source temperatures were 250°C and 200°C, respectively. Twenty scans were recorded over the 85-500 m/z mass range using the Advanced Scanning Speed Protocol (ASSP, Shimadzu Co).
Data Processing
Data processing was performed as previously described. 20 Briefly, MS data were exported in the netCDF format, and peak detection and alignment were performed using MetAlign software (Wageningen UR, The Netherlands). 21 The resulting data were exported in the CSV format file and analyzed using in-house analytical software (AI output) that enables peak identification and quantification using our in-house metabolite library. For quantification, the peak height of each ion was calculated and normalized using the peak height of 2-isopropylmalic acid as the internal standard.
Statistical Analysis
Data are expressed as mean ± standard error. We evaluated the extreme outliers with a Smirnov-Grubbs' test. Differences in categorical variables were analyzed by Pearson's chi-squared test. Differences among the 3 groups were assessed using oneway analysis of variance followed by Bonferroni's multiple comparison tests. When the obtained data did not represent a normal distribution, the Kruskal-Wallis test was performed followed by Dunn's test as a post hoc test. Correlations among variables were examined using Spearman rank correlation coefficient and linear regression. P<0.05 was considered statistically significant.
Results
Patient Characteristics
The characteristics of each patient group are presented in Table 1 . There was no significant difference in the rate of use of a bare metal stent among all 3 groups. There was also no significant difference in the coronary risk factor profiles between the minor restenosis group and the major restenosis group. Most patients in the de novo group had been prescribed β-hydroxy-β-methylglutaryl coenzyme A reductase inhibitors (statins). The serum low-density lipoprotein cholesterol (LDL-C) levels were significantly lower in the de novo group than in the minor restenosis group.
Restenosis and Hydrophilic Metabolomics in Serum
GC/MS analysis of serum hydrophilic metabolites detected 83 metabolites ( Table 2) . Surprisingly, the metabolomic profiles of the major restenosis group were significantly different from those of the minor restenosis group. Eight metabolites -isobutylamine, sarcosine, homoserine, ribulose, taurine, glutamine, glucose, and tryptophan -were all significantly altered in the major restenosis group compared with the minor restenosis group (Figure 2 ).
In the de novo lesion group, only one metabolite -isobutylamine -was significantly altered compared with the minor restenosis group (Figure 2) .
Correlations of Individual Metabolites
We examined correlations among these 8 metabolites -isobutylamine, sarcosine, homoserine, ribulose, taurine, glutamine, glucose, and tryptophan -using Spearman rank correlation (Figure 3) . Isobutylamine was negatively correlated with sarcosine (r=−0.31, P<0.05), taurine (r=−0.32, P<0.05), glutamine (r=−0.52, P<0.001), and tryptophan (r=−0.36, P<0.05). Sarcosine was positively correlated with homoserine (r=0.38, P<0.01), glutamine (r=0.49, P<0.001), and tryptophan (r=0.32, P<0.05). Homoserine was positively correlated with taurine (r=0.45, P<0.01), glutamine (r=0.53, P<0.001), and tryptophan (r=0.47, P<0.01). Taurine was positively correlated with glutamine (r=0.64, P<0.001), glucose (r=0.33, P<0.05), and tryptophan (r=0.77, P<0.001). Glutamine was positively correlated with tryptophan (r=0.71, P<0.001).
In the major restenosis group, 8 out of 28 pairs of metabolites showed significant correlations (Figure 4) . Sarcosine was positively correlated with homoserine (r=0.61, P<0.01), taurine (r=0.59, P<0.01), glutamine (r=0.70, P<0.001), and tryptophan (r=0.43, P<0.05). Homoserine was positively correlated with taurine (r=0.56, P<0.01) and glutamine (r=0.70, P<0.001). Ribulose was positively correlated with glucose (r=0.56, P<0.01). Taurine was positively correlated with glutamine (r=0.62, P<0.01).
Discussion
In this study, we investigated the serum metabolomic profiles of CAD patients with major restenosis, minor restenosis, and de novo stenotic lesions. The serum metabolomic profiles were significantly different between patients with major and minor restenosis. The degree of restenosis was characterized during follow-up angiography performed by well-trained vascular interventionists who were not associated with our study. To our knowledge, this is the first study to comprehensively analyze serum metabolites and identify alterations in the metabolomic profiles specific to stent restenosis.
The guidelines for the secondary prevention of coronary atherosclerotic diseases issued by the AHA recommend that serum LDL-C should be maintained below 100 mg/dl for all patients with atherosclerotic disease. In addition, the AHA strongly recommends that LDL-C should be maintained below 70 mg/dl in patients with coronary heart disease (CHD). 22, 23 Unfortunately, these treatment guidelines do not control atherosclerotic disease in all CHD patients despite appropriate treatment. Therefore, cardiologists need minimally invasive methods for identifying restenosis-prone patients and administering more intensive treatment. A novel biomarker for restenosis-prone conditions would therefore be extremely useful for the successful secondary prevention of coronary atherosclerotic disease. Recent reports have shown that N-terminal pro-hormone brain natriuretic peptide, cystatin C, CRP, interleukin-6, and albuminuria may all be useful for discriminating between cardiovascular events. 24 However, these biomarkers, which are more indicative of inflammation, are not specific to coronary atherosclerotic diseases and may not be the most appropriate indicators of restenosis.
Our data indicate that disease-specific patterns can be identified in the serum metabolomic profile, distinguishing patients with major restenosis from those with minor lesions even though all patients were treated according to the AHA guide- lines and had similar coronary risk factors. Importantly, there were no significant differences in the risk factors for coronary atherosclerotic disease between the patients with major and minor restenosis; these 2 patient groups were only distinguishable by alterations in the diagnostic markers in their serum metabolomic profiles. The levels of 8 serum metabolites -isobutylamine, sarcosine, homoserine, ribulose, taurine, glutamine, glucose, and tryptophan -were significantly different between the major and minor restenosis groups. Isobutylamine, which is known to promote serotonin release from platelets, was significantly higher in patients with major restenosis than in those with minor restenosis. 25 Serotonin, the primary amine 5-hydroxytryptamine, is a hormone that exerts multiple pro-atherogenic Figure 2 . The levels of 8 metabolites - isobutylamine, sarcosine, homoserine, ribulose, taurine, glutamine, glucose, and tryptophan - were found to be significantly different in the major restenosis group compared with the minor restenosis group. The levels of 2 metabolites were found to be significantly different in the de novo group compared with the minor restenosis group. AU indicates an arbitrary unit; 1 arbitrary unit is defined as the mean serum concentration in the minor restenosis group. *P<0.05, **P<0.01. HASOKAWA M et al. effects in the vasculature, including vasoconstriction and endothelial and smooth muscle cell mitogenesis. 26, 27 It is widely known that restenosis following stent implantation is caused by proliferation of vascular smooth muscle cells. Thus, increased isobutylamine may be directly related to stent restenosis. In contrast, homoserine and glutamine were decreased significantly in the major restenosis patients. Homoserine reportedly inhibits vasoconstriction in porcine blood vessels, and glutamine increases nitric oxide (NO) production, which is an inhibitor of smooth muscle contraction in blood vessels. 28,29 Therefore, lower levels of homoserine and glutamine may contribute to stent restenosis. Tryptophan was also significantly lower in the serum of major restenosis patients. Tryptophan is commonly included in the conservation medium for graft vessels, and it may be necessary for vascular protection. 30 However, its precise role is not completely understood to date. Taurine is a free amino acid, many of which exist in vivo, and it is known that it has various physiological effects. 31 Zhang et al reported that vascular smooth muscle cell proliferation was inhibited by taurine treatment. 32 Therefore, there might be a close relationship between the decrease in taurine in serum and the progression of restenosis. Glucose and ribulose are monosaccharide. There were significant differences in the fasting blood monosaccharide levels between the major restenosis group and the minor restenosis group, although there was no significant difference in the value of HbA1c between them. Thus, glucose metabolism while fasting could be a risk factor for major restenosis. Sarcosine is a naturally produced amino acid in viscera, such as muscles. To our knowledge, there are no reports that show the relationship between sarcosine and arteriosclerosis. Further studies would be required to understand the relationship between the decrease in sarcosine level and arteriosclerosis. Interestingly, the minor restenosis group and the major restenosis group showed the different metabolite-pairs that had correlations. This result indicates that there might be some differences in the activation of metabolic pathways between these 2 patient groups.
Isobutylamine was significantly higher in the patients with de novo lesions than those with minor restenosis. This metabolite may participate in thrombus formation through promoting serotonin release from platelets. 25 However, because there were differences in patient background between the de novo and minor restenosis groups, and thrombi may have been present in systemic as well as coronary vessels, the fact that isobutylamine was associated with thrombosis in these patients remains uncertain.
Serum metabolomic profiling can be used to identify pathological conditions for many diseases, including cancer, diabetes, and atherosclerosis. 33-36 Moreover, disease diagnosis based on serum metabolomic profiling is now considered to be clinically applicable. Our results indicate that serum metabolomic profiles, in combination with the consideration of conventional coronary risk factors, are an important aid for the successful secondary prevention of coronary atherosclerotic diseases.
This study had a few limitations. Although a correlation between the abovementioned metabolites and restenosis was established, the reason for changes in their levels according to the degree of stent restenosis remained unclear. It is also unclear whether these metabolites were a cause or a result of restenosis. Therefore, further investigations are required to understand the cause and effect relationship between these metabolites and restenosis progression. In addition, the present study included only a small number of patients; additional studies using a larger patient population should be conducted to fully evaluate the efficacy of metabolomic profiling in the prevention and management of restenosis.
Conclusions
As per our knowledge, this was the first study to conduct GC/ MS-based hydrophilic metabolomic profiling in patients with cardiovascular disease. It is also the first to identify alterations in the levels of 8 important metabolites (isobutylamine, sarcosine, homoserine, ribulose, taurine, glutamine, glucose, and tryptophan) that are indicative of stent restenosis. This study provides the first evidence of the efficacy of serum metabolomic profiling in the identification of specific fingerprints as biomarkers of stent restenosis.
